OPID (SA)

Active
VAT

BE 0884.084.724

Full name
Omega Pharma Innovation & Development
Address
Gaston Crommenlaan 6/606
9050 Gent
Established
04-10-2006
Principal activity
Research and experimental development on biotechnology

Crisis resilience of OPID

Which companies are best armed against current economic trends and the energy crisis?

Read more

Financial data of OPID

2022 Financial statements 2021 Financial statements 2020 Financial statements 2019 Financial statements
Turnover €49,139,158
10%
€44,673,298
1%
€44,057,699
-28%
€60,854,929
Profit/Loss €1,988,571
120%
-€9,851,355
95%
-€186,073,005
-309%
-€45,484,594
Equity €123,398,094
2%
€121,409,522
-56%
€274,825,457
-40%
€460,898,461
Gross margin €23,076,082
40%
€16,474,805
11%
€14,888,867
-55%
€32,865,199
Employees 44,5 FTE
-5%
46,7 FTE
-1%
47 FTE
6%
44,5 FTE

Frequently asked questions

What is the VAT number of Omega Pharma Innovation & Development?
The VAT number of Omega Pharma Innovation & Development is BE0884084724.
When was Omega Pharma Innovation & Development founded?
Omega Pharma Innovation & Development was founded on 04-10-2006.
What is the address of Omega Pharma Innovation & Development?
The current registered office of Omega Pharma Innovation & Development is located at Gaston Crommenlaan 6/606, 9050 Gent.
When was the last time Omega Pharma Innovation & Development filed their annual financial statements?
The most recent financial statements of Omega Pharma Innovation & Development were filed on 01-06-2023. You can view them here.
How many employees does Omega Pharma Innovation & Development have?
There are 44,5 FTEs working at Omega Pharma Innovation & Development according to the staff figures in the most recent financial statements.
What is the annual turnover of Omega Pharma Innovation & Development?
At the time of its most recent financial statements, Omega Pharma Innovation & Development recorded a total turnover of €49,139,156.00.
Address

  You have disabled Javascript on your computer. To use this website, please enable Javascript first.


More details